The subsidiary company of Beijing Centergate Technologies (000931.SZ), SGLT-II Metformin Tablets, obtained acceptance for its application for market approval.

Beijing Centergate Technologies (000931.SZ) announced that its subsidiary company Duodu Pharmaceutical Co., Ltd. (hereinafter referred to as Duodu Pharmaceutical) recently received the "Acceptance Notice" issued by the National Medical Products Administration (hereinafter referred to as the NMPA). The application for the marketing authorization of Sitagliptin Metformin Hydrochloride Tablets (II) (specification: each tablet contains Sitagliptin Phosphate 50mg (calculated as Sitagliptin) and Metformin Hydrochloride 850mg) has been accepted. Duodu Pharmaceutical's Sitagliptin Metformin Hydrochloride Tablets (II) (specification: each tablet contains Sitagliptin Phosphate 50mg (calculated as Sitagliptin) and Metformin Hydrochloride 850mg) was initiated for development in 2023. Its indications are: This product is used in combination with diet and exercise therapy for patients with type 2 diabetes who have inadequate blood sugar control with Metformin monotherapy or are receiving combined therapy with both medications.